Outlook For AstraZeneca/AtheroGenics’ Candidate May Sink On ARISE Trial Results
This article was originally published in The Pink Sheet Daily
Executive Summary
A Phase III clinical study evaluating the atherosclerosis candidate failed to meet its primary endpoint.
You may also be interested in...
AtheroGenics To Lay Off Half Its Workforce On Heels Of ARISE Failure, AstraZeneca Pullout
Initiative will free up funds needed to file NDA on AGI-1067 without former partner AstraZeneca.
AtheroGenics To Lay Off Half Its Workforce On Heels Of ARISE Failure, AstraZeneca Pullout
Initiative will free up funds needed to file NDA on AGI-1067 without former partner AstraZeneca.
AstraZeneca Accelerates Biologics Strategy With Acquisition Of MedImmune
Following the merger, valued at roughly $15.6 billion, 27 percent of AstraZeneca’s portfolio will be in biologics.